Rosetta launches next-gen cancer panel
Rosetta Genomics has announced the commercial launch of OncoGxOne, Admera Health’s next-generation sequencing panel that detects genetic alterations implicated in cancer to provide clear, concise, and actionable clinical recommendations from a single test.
Rosetta said OncoGxOne interrogates all types of genomic aberrations in 64 genes, specifically 56 related to cancer targeted therapy and eight related to chemotherapy. The test is performed on a modest-sized pathology sample in the standard format of formalin-fixed, paraffin-embedded tissue, the same as Rosetta’s other clinical microRNA-based diagnostics.